N/A N=11 HSG and Tubal Patency Study
Tubal Patency
Primary: Number of Participants With Bilateral Tubal Patency as Assessed by HSG-follicular — 9; 1 Participants — p=0.4795
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
N/A N=45 Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
Type 2 Diabetes · Obesity
Primary: HbA1c (%) Measured at Week 52 — 7.3 % glycated hemoglobin
Phase 2 N=82 CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Patients Removed From Study Treatment Due to Toxicities — 31 participants
Phase 4 N=10 Use of Negative Pressure Wound Therapy in High Risk Surgical Closed Incisions
High Risk Abdominal Wounds
Primary: Number of Participants With Surgical Site Infections Within 1 Month (4 Weeks ) From Index Operation — 1 Participants
Phase 3 N=433 Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
Hepatitis A
Primary: Number of Seropositive Subjects for Anti-HAV Antibodies — 106; 94 Participants
N/A N=331 Improving Care for Children With Complex Needs
Medically Complex Children · Care Coordination · Case Manager
Primary: Cost of Care — 71692; 70618; 37,677; 56702 US Dollars
N/A N=58 Impact on Instructional Video on Patients' Compliance With Preparation During CT Planning for Prostate Cancer
Latent Cancer (Prostate)
Primary: Number of Participants Whom Had Proper Preparation After Education Intervention — 22; 22; 7; 7 participants
Phase 4 N=56 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
Idiopathic Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months — 12; 10; 9 LVEF responders — p=0.685
Phase 2 N=17 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: PSA Response as Defined by the Recommendations of the Prostate-Specific Antigen Working Group — 0 participants
N/A N=294 EMPOWER Clinical Trial: Vagal Blocking for Obesity Control
Obesity
Primary: Percentage of Excess Weight Loss (EWL) With the Maestro System — 17; 16 Percentage of excess weight loss
Phase 2 N=36 Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
Recurrent Melanoma · Stage IA Melanoma · Stage IB Melanoma
Primary: T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide — 0.02; 0.01; 0.97; 0.98 % of CD8+ T cells — p=<.001
N/A N=5 Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
Primary: Number of LDLR Gene Mutations — 7 gene mutations
Phase 2 N=19 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
Adult Brain Tumor
Primary: Number of Participants With Objective Response — 3; 1; 5; 9 Participants
N/A N=100 The Impact of Contraception on Postpartum Weight Loss
Weight
Primary: Weight — 3.2; 6.8; 7.0 percent weight lost — p=<0.05